Tag - HGEN

HCW starts Humanigen at buy; PT $31

H.C. Wainwright launched coverage of Humanigen (NASDAQ:HGEN) with a “buy” rating and price target of $31. The stock closed at $12.03 on Oct. 13. The company’s lead asset, lenzilumab, is an antibody targeting...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.